Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Cantargia reports launch of investigator-led lung cancer prevention study

Cantargia (STO: CANTA) has announced that the first patient has been dosed in a Phase 2 clinical trial investigating nadunolimab in up to 59 current or previous smokers with multifocal high-risk lung nodules, and at...

June 10, 2026

Developments

Sensorion selects SENS-601 for hearing loss as lead program; files for trials in Canada and France

Sensorion (EPA: ALSEN) announced the selection of SENS-601 which addresses GJB2-related hearing loss as its lead program. A clinical trial application has been filed in Canada and France to evaluate the safety...

June 10, 2026

Developments

Cullinan shares data from T cell engager programs targeting autoimmune diseases

Cullinan Therapeutics (NASDAQ: CGEM) has reported clinical data and outlined global clinical development plans for CLN-978, a CD19xCD3 T cell engager, and velinotamig, a BCMAxCD3 T cell engager, in autoimmune diseases...

June 10, 2026

Developments

INOVATE selects Perimeter for contribution to advance AI for breast cancer surgery

Perimeter Medical Imaging (TSXV: PINK; OTCQX: PYNKF) has announced it has been selected to receive a contribution from the INOVAIT Pilot Fund to advance next-generation AI capabilities for its flagship product Claire...

June 9, 2026

Developments

FDA clears Pentixapharm IND for cardiovascular diagnostic program

Pentixapharm Holding (Frankfurt Prime Standard: PTP) has announced that the FDA has cleared its Investigational New Drug (IND) application for its lead CXCR4-targeted diagnostic program in treatment resistant...

June 9, 2026

Developments

ZEO adds nine experts in regenerative and longevity medicine to advisory board

ZEO ScientifiX (OTCQB: ZEOX) has announced the expansion of its medical advisory board with the addition of nine physicians and scientific innovators across key disciplines in regenerative and longevity medicine. The...

June 9, 2026

Developments

Eledon reports insulin independence in islet transplant patients treated with tegoprubart

Eledon Pharmaceuticals (NASDAQ: ELDN) announced updated results from an investigator-initiated trial evaluating tegoprubart, its investigational anti-CD40L antibody, as part of a calcineurin inhibitor-free...

June 8, 2026

Developments

Seaport reports positive dose data from trial of GlyphAgo for anxiety

Seaport Therapeutics (NASDAQ: SPTX) has announced positive data from the multiple-ascending dose portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo (SPT-320), a novel, Glyphed...

June 8, 2026

Developments

Shattuck announces Phase 1 results for SL-325 antibody

Shattuck Labs (NASDAQ: STTK) has announced data from its Phase 1 trial evaluating the safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamics, and immunogenicity of SL-325, its lead DR3 blocking...

June 8, 2026

Developments

ANSM grants clearance for Anteris trial of transcatheter heart valve

Anteris Technologies Global (NASDAQ: AVR; ASX: AVR) has received full regulatory clearance from the French National Agency for Medicines and Health Products Safety (ANSM) enabling patient recruitment to begin in France...

June 8, 2026

Developments

MindBio launches AI software for drug use and fatigue detection

MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) has launched its lead commercial software Intox AI for validation and testing of intoxication and fatigue. Intox AI enables new analytical capabilities to...

June 5, 2026

Developments

TelyRx commences trading on OTCQX

TelyRx Holdings (TSX: TELY; OTCQX: TELYF) has announced that its subordinate voting shares will commence trading on the OTCQX Best Market (OTCQX), the premier tier of the OTC Markets Group in the U.S., under the symbol...

June 5, 2026

Developments

Profound Medical’s TULSA procedure highlighted on popular podcast, Over 50 & Flourishing

In a recent two-part Over 50 & Flourishing video and podcast, host Dominique Sachse sat down with her husband, voice actor and singer Vic Mignogna, to discuss his health journey, including a diagnosis of prostate...

June 4, 2026

Developments

VolitionRx files patent for Ebola triage and treatment monitoring test

VolitionRx (NYSE AMERICAN: VNRX) has announced the filing of a strategic patent application covering the use of its proprietary Nu.Q technology in triaging and monitoring patients who are suspected of having contracted...

June 3, 2026

Developments

AACN journal publishes study showing benefits of ENvue’s feeding tube guidance platform

ENvue Medical (NASDAQ: FEED) has announced that Critical Care Nurse, the official journal of the American Association of Critical-Care Nurses (AACN), has published an independent, peer-reviewed study showing significant...

June 3, 2026

Developments

Firefly discovers novel electrophysiological biomarker for PTSD

Firefly Neuroscience (NASDAQ: AIFF) has announced the identification of a novel electrophysiological biomarker for Post-Traumatic Stress Disorder (PTSD) using brain scans collected on its FDA-510(k)-cleared Evoke System...

June 2, 2026

Developments

Senzime launches new EMG sensor for anesthesia monitoring

Senzime (STO: SEZI; OTCQX: SNZZF) has announced the launch of its TetraSens electromyography (EMG) sensor for use with the TetraGraph Train-of-Four monitoring system for anesthesia monitoring. According to Senzime, the...

June 1, 2026

Developments

Sunshine announces Canadian approval of generic Rivaroxaban

Sunshine Biopharma (NASDAQ: SBFM) has announced the Canadian approval of Rivaroxaban—its generic equivalent of the brand Xarelto—in tablets of 2.5 mg, 10 mg, 15 mg, and 20 mg for the treatment and prevention of deep...

June 1, 2026

Developments

Cercare and Siemens announce global collaboration on CBCT-P guided stroke treatment

Closely held Cercare Medical and Siemens Healthineers (FSE: SHL) have announced a global collaboration to accelerate the adoption of Cone-Beam CT Perfusion (CBCT-P) in acute stroke care, leveraging its capability to...

May 28, 2026

Developments

BioXcel presents positive data for BXCL501 in bipolar or schizophrenia at ASCP

BioXcel Therapeutics (NASDAQ: BTAI) has announced new positive Phase 3 SERENITY At-Home data for BXCL501 in agitation associated with bipolar disorders or schizophrenia, to be presented this week at the 2026 American...

May 28, 2026

Developments

Conexeu launches preclinical program for B.R.E.A.S.T. with WFIRM

Conexeu Sciences (NASDAQ: CNXU) has initiated a preclinical development program for B.R.E.A.S.T. (BIO-REGENERATIVE ERGONOMICALLY ARCHITECTED SMART TISSUE), its recently unveiled 3D-printed bioregenerative breast matrix...

May 28, 2026

Developments

The iMRI revolution gets another boost from AiM’s collaboration with Siemens to advance robotic neurosurgery

Closely held AiM Medical Robotics has announced a collaboration agreement with Siemens Healthineers (FSE: SHL) for the implementation of an interface enabling AiM’s robotic platform to operate with MRI systems...

May 27, 2026

Subscribe